Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  Valneva SE    VLA   FR0004056851

VALNEVA SE

(VLA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Valneva SE : Volatility should make a big comeback

04/08/2021 | 06:07am EDT
long trade
Live
Entry price : 10.9€ | Target : 14.9€ | Stop-loss : 9.75€ | Potential : 36.7%
After several weeks of range-bound movement, shares in Valneva SE could enter into a new clear trend. The exit out of the current trading range could be the signal for a return of volatility.
Investors have an opportunity to buy the stock and target the € 14.9.
Valneva SE : Valneva SE : Volatility should make a big comeback
Summary
  • The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.

Strengths
  • Graphically speaking, the timing seems perfect for purchasing the stock close to the EUR 8.99 support.
  • The prospective high growth for the next fiscal years is among the main assets of the company
  • Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • The equity is one of the most attractive in the market with regard to earnings multiple-based valuation.
  • Over the past year, analysts have regularly revised upwards their sales forecast for the company.
  • Over the last seven days, analysts have been revising upwards their EPS estimates for the company.
  • For several months, analysts have been revising their EPS estimates roughly upwards.
  • For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • Within the weekly time frame the stock shows a bullish technical configuration above the support level at 7.51 EUR

Weaknesses
  • Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
  • With an enterprise value anticipated at 8.56 times the sales for the current fiscal year, the company turns out to be overvalued.
  • The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
Ratings chart
Subsector Other Biotechnology & Medical Research
1st jan.Capitalization (M$)Investor Rating
VALNEVA SE60.39%1 359
MODERNA, INC.33.44%55 833
LONZA GROUP AG-5.70%43 206
IQVIA HOLDINGS INC.16.21%39 822
CELLTRION, INC.-13.51%37 710
SEAGEN INC.-19.65%25 513
HANGZHOU TIGERMED CONSULTIN..-15.83%17 802
INCYTE CORPORATION-8.07%17 559
PHARMARON BEIJING CO., LTD.21.57%17 208
ALNYLAM PHARMACEUTICALS, IN..3.89%15 842
BIO-TECHNE CORPORATION26.92%15 638
More Results

© MarketScreener.com 2021

Disclaimer: The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.

Financials
Sales 2021 185 M 220 M 220 M
Net income 2021 68,1 M 81,1 M 81,1 M
Net cash 2021 30,5 M 36,3 M 36,3 M
P/E ratio 2021 16,6x
Yield 2021 -
Capitalization 1 141 M 1 359 M 1 357 M
EV / Sales 2021 6,02x
EV / Sales 2022 1,85x
Nbr of Employees 500
Free-Float 69,8%
Upcoming event on VALNEVA SE
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Average target price 12,42 €
Last Close Price 12,43 €
Spread / Highest target 8,61%
Spread / Average Target -0,08%
Spread / Lowest Target -13,9%
EPS Revisions
Managers and Directors
NameTitle
Thomas Lingelbach Co-President & Chief Executive Officer
Franck Charles Marie Grimaud Co-President & Chief Business Officer
Frédéric Grimaud Chairman-Supervisory Board
Michael Möhlen Vice President-Technical Development
Andreas Meinke VP-Preclinical & Translational Research